Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of “Moderate Buy” from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has received an average recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $220.75.

Several brokerages have commented on CRL. Evercore restated an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research report on Monday. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Finally, Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th.

Insider Activity at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp grew its stake in shares of Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after acquiring an additional 1,074 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Charles River Laboratories International in the first quarter worth $418,000. American Century Companies Inc. lifted its position in shares of Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in Charles River Laboratories International by 3.9% during the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 4.7%

Shares of Charles River Laboratories International stock opened at $228.99 on Friday. Charles River Laboratories International has a 1 year low of $144.26 and a 1 year high of $238.85. The business has a 50-day moving average of $197.28 and a two-hundred day moving average of $187.23. The company has a market capitalization of $11.03 billion, a P/E ratio of -60.90, a price-to-earnings-growth ratio of 2.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same quarter last year, the firm posted $2.34 earnings per share. Charles River Laboratories International’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts predict that Charles River Laboratories International will post 11.05 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.